Ziyadeh F N, Han D C, Cohen J A, Guo J, Cohen M P
Department of Medicine, University of Pennsylvania, Philadelphia, USA. ziyadeh @ mail.med.upenn.edu
Kidney Int. 1998 Mar;53(3):631-8. doi: 10.1046/j.1523-1755.1998.00815.x.
Albumin modified by Amadori glucose adducts, formed in increased amounts in diabetes, stimulates collagen IV production and gene expression in renal glomerular mesangial cells, and induces mesangial matrix accumulation accompanied by increased mRNA encoding alpha 1 (IV) collagen and fibronectin in diabetic animals. These effects contribute to the pathogenesis of diabetic nephropathy, and resemble biologic activities of the cytokine TGF-beta 1, which also has been causally implicated in diabetic renal disease. We postulated that Amadori-modified glycated albumin modulates TGF-beta 1 expression in mesangial cells, and that TGF-beta 1 participates in mediating the glycated albumin-induced increases in mesangial cell matrix production. To test this hypothesis, we measured mRNA encoding TGF-beta 1, the TGF-beta Type II receptor and fibronectin, a key matrix component of the TGF-beta 1 tissue response, after incubation of mesangial cells with glycated albumin. Steady state levels of the mRNAs encoding for these proteins were stimulated when mesangial cells were cultured in the presence of albumin containing Amadori glucose adducts compared with levels in cells cultured with the nonglycated, glucose-free counterpart. The glycated protein-induced changes in mRNA expression were observed with concentrations of glycated albumin encompassing those found in clinical specimens and in media containing physiologic (5.5 mM) glucose concentrations, indicating that they were due to the glucose-modified protein and not to a hyperglycemic milieu. Further, they were accompanied by increased translated fibronectin protein, which was prevented with TGF-beta neutralizing antibody, as was the glycated albumin-induced increase in fibronectin mRNA. The findings indicate that Amadori-modified glycated albumin stimulates mesangial cell TGF-beta 1 gene expression by mechanisms that are operative under normoglycemic conditions. These data provide the first link between elevated glycated serum albumin concentrations and increased TGF-beta 1 bioactivity in the pathogenesis of mesangial matrix accumulation in diabetes.
在糖尿病中生成量增加的经阿马多利葡萄糖加合物修饰的白蛋白,可刺激肾小球系膜细胞中IV型胶原蛋白的产生和基因表达,并在糖尿病动物中诱导系膜基质积聚,同时伴有编码α1(IV)胶原蛋白和纤连蛋白的mRNA增加。这些作用有助于糖尿病肾病的发病机制,并且类似于细胞因子转化生长因子β1(TGF-β1)的生物学活性,而TGF-β1也与糖尿病肾病有因果关系。我们推测经阿马多利修饰的糖化白蛋白可调节系膜细胞中TGF-β1的表达,并且TGF-β1参与介导糖化白蛋白诱导的系膜细胞基质产生增加。为了验证这一假设,我们在用糖化白蛋白孵育系膜细胞后,测量了编码TGF-β1、TGF-β II型受体和纤连蛋白(TGF-β1组织反应的关键基质成分)的mRNA。与用未糖化、无葡萄糖的对照白蛋白培养的细胞相比,当系膜细胞在含有阿马多利葡萄糖加合物的白蛋白存在下培养时,编码这些蛋白质的mRNA的稳态水平受到刺激。在用涵盖临床标本和含有生理(5.5 mM)葡萄糖浓度的培养基中发现的糖化白蛋白浓度时,观察到糖化蛋白诱导的mRNA表达变化,这表明它们是由葡萄糖修饰的蛋白质引起的,而不是高血糖环境。此外,它们伴随着翻译后的纤连蛋白增加,而TGF-β中和抗体可阻止这种增加,糖化白蛋白诱导的纤连蛋白mRNA增加也可被阻止。这些发现表明,经阿马多利修饰的糖化白蛋白通过在正常血糖条件下起作用的机制刺激系膜细胞TGF-β1基因表达。这些数据在糖尿病系膜基质积聚的发病机制中,首次建立了糖化血清白蛋白浓度升高与TGF-β1生物活性增加之间的联系。